Folate and Canker Sores — Deficiency, MTHFR, and What to Take

TL;DR

Folate deficiency is identified in a meaningful subset of recurrent aphthous stomatitis (RAS) patients across multiple studies — estimates range from 14–38% of RAS patients having below-normal serum folate versus 3–10% of controls. Correcting folate deficiency reduces outbreak frequency. The complication: roughly 40% of the population carries a common MTHFR gene variant that significantly impairs conversion of dietary folic acid into 5-methyltetrahydrofolate (5-MTHF), the bioactive form the body actually uses. If you're in this group and supplementing with standard folic acid, you may see minimal benefit. The practical recommendation: supplement with methylfolate (the pre-converted form, also called 5-MTHF or L-methylfolate) rather than folic acid, particularly if you've tried folic acid before without effect.

Folate's Role in Oral Mucosal Health

Folate (Vitamin B9) is a B-vitamin essential for DNA synthesis, cell division, and methylation reactions. It is particularly critical in rapidly dividing tissues — and the oral mucosa is one of the most rapidly renewing epithelial surfaces in the body. Oral mucosal cells turn over every 7–14 days.

When folate is deficient:

• DNA synthesis is impaired in rapidly dividing epithelial cells — this produces abnormal cell maturation and increases vulnerability to ulceration
• Homocysteine accumulates — folate is required to remethylate homocysteine to methionine; elevated homocysteine is directly cytotoxic to endothelial and epithelial cells
• Immune cell production is reduced — lymphocyte proliferation and natural killer cell activity both depend on adequate folate
• Mucosal integrity weakens — the barrier function of the oral epithelium depends on normal cell turnover

The result is mucosa that is thinner, more vulnerable to minor trauma, and slower to repair — all conditions that increase the probability and severity of aphthous ulcers.

The Evidence: Folate in RAS Patients

Multiple studies across different populations have identified folate deficiency at elevated rates in RAS patients compared to controls:

Wray et al. (1975 — PMID: 1165839) — One of the earliest systematic evaluations: found B12, folate, or iron deficiency in 20% of 330 RAS patients. Among patients with deficiency, correction of the deficient nutrient led to significant clinical improvement in outbreak frequency.

Challacombe et al. (1983 — PMID: 6301481) — Serum folate levels in RAS patients were significantly lower than controls in a British cohort. Patients with major aphthous ulcers had lower levels than those with minor aphthous ulcers.

Field et al. (1987 — PMID: 3473407) — Confirmed lower serum folate in RAS patients and found that 18% of their RAS cohort was below the lower limit of normal for serum folate.

Nolan et al. (1991 — PMID: 2017188) — Prospective study finding hematinic deficiencies (B12, folate, iron) in 20% of RAS patients. Supplementation in deficient patients reduced clinical severity.

The evidence base is consistent but important to characterize honestly: most of these are deficiency-correction studies — they demonstrate that correcting folate deficiency helps patients who are deficient. There is no RCT demonstrating that supplementing folate in non-deficient RAS patients prevents outbreaks the way Vitamin B12 supplementation was shown to work even in non-deficient patients (Volkov et al., 2009 — PMID: 19530214).

If you're not folate deficient, the case for folate supplementation is weaker. If you are deficient — or haven't tested — correction is a reasonable first step.

The MTHFR Problem: Why Folic Acid May Not Work for You

This is the piece that most online advice misses.

Folic acid — the synthetic form of folate in most supplements and fortified foods — is not bioactive. It must be converted through a four-step enzymatic pathway before the body can use it. The final and rate-limiting step is catalyzed by an enzyme called MTHFR (methylenetetrahydrofolate reductase), which converts 5,10-methyleneTHF into 5-methylTHF (5-MTHF), the active circulating form.

The MTHFR gene is polymorphic. Two variants are clinically relevant:

• C677T — Reduces MTHFR enzyme activity by approximately 30–65% in heterozygotes and up to 70% in homozygotes
• A1298C — Moderate activity reduction; compound heterozygosity (one copy of each) produces clinically significant impairment

Population prevalence: The C677T variant is carried by approximately 40–60% of most populations in heterozygous form (one copy); 10–15% are homozygous (two copies). Prevalence varies by ancestry — higher in southern European, Mexican, and some Middle Eastern populations.

The practical consequence: In people with significant MTHFR impairment, supplementing folic acid may not meaningfully raise 5-MTHF levels. Unmetabolized folic acid can accumulate and may actually competitively inhibit folate receptors, potentially worsening the functional deficiency.

The solution: Supplement with 5-methyltetrahydrofolate (5-MTHF) directly, also sold as:

• L-methylfolate
• Methylfolate
• Levomefolic acid (the pharmaceutical form)
• (5-MTHF) on product labels

This form bypasses the MTHFR conversion step entirely. It is absorbed and available regardless of your MTHFR genotype.

Food Folate vs. Supplemental Folic Acid: Different Bioavailability

An underappreciated nuance: the folate in food is not the same as folic acid in supplements, and neither is as straightforward as it seems.

Food folate exists in multiple chemical forms, primarily as polyglutamate conjugates. Before absorption, the intestinal enzyme folylpolyglutamate hydrolase must break these down into monoglutamates. This conversion is efficient but incomplete — the bioavailability of food folate is estimated at 50–80% under optimal conditions, lower when gut mucosa is compromised (as in celiac disease or Crohn's).

Folic acid (the synthetic supplement form) is actually more bioavailable than food folate under normal conditions — roughly 85–100% when taken on an empty stomach — but must still be converted by MTHFR to become active. In MTHFR-impaired individuals, higher bioavailability doesn't help if the downstream conversion is bottlenecked.

Methylfolate sidesteps both issues — it's the active form, requires no intestinal conversion and no MTHFR activity, and is absorbed directly. This is why it's the preferred form for people with MTHFR variants and for anyone with intestinal absorption concerns.

The practical implication: eating more spinach helps up to a point, but if you have MTHFR impairment and marginal folate status, dietary increases won't fully correct functional deficiency. Methylfolate supplementation is more reliable.

The Folate–B12 Masking Problem

This is clinically important and often overlooked: high-dose folic acid supplementation can mask B12 deficiency on blood tests while neurological damage from B12 deficiency continues.

Here's the mechanism: both folate and B12 are required for normal red blood cell development. When either is deficient, red blood cells become large and abnormal (megaloblastic anemia). If you supplement high-dose folic acid while B12 is deficient, the folate corrects the red blood cell abnormality — the complete blood count looks normal — while B12 deficiency persists and progresses. Neurological damage from B12 deficiency (peripheral neuropathy, cognitive changes) can advance for months while routine blood work appears normal.

This is why the clinical guidance is clear: do not supplement high-dose folic acid alone without also checking B12 status, and ideally address both deficiencies together.

For canker sore purposes, this matters because B12 and folate are commonly deficient together (both in the same methylation pathway, both depleted by similar conditions), and the combination product approach — methylcobalamin plus methylfolate — avoids the masking problem entirely while addressing both mechanisms.

Medications That Deplete Folate

Several common medications directly interfere with folate metabolism or absorption. If you're on any of these and experiencing recurrent canker sores, folate status is worth checking:

Methotrexate — A folate antagonist by design. Used in rheumatoid arthritis, psoriasis, Crohn's, and some cancers, methotrexate works by blocking dihydrofolate reductase — a key enzyme in folate metabolism. Oral ulcers are a recognized side effect. Folic acid (or methylfolate) supplementation is standard when methotrexate is prescribed for autoimmune conditions, specifically to mitigate mucosal side effects. See also Lupus and Canker Sores for the methotrexate-oral ulcer interaction in that context.

Sulfasalazine — Used in inflammatory bowel disease and rheumatoid arthritis. Competitively inhibits folate absorption in the gut. RAS is a recognized extraintestinal manifestation of IBD, and sulfasalazine adds a folate-depletion layer on top of disease-related malabsorption.

Phenytoin and other anticonvulsants — Phenytoin (Dilantin), carbamazepine, and valproate all reduce folate levels through various mechanisms (reduced absorption, increased metabolism). Long-term anticonvulsant use is a recognized cause of folate deficiency.

Trimethoprim (in Bactrim) — An antibiotic that functions by inhibiting dihydrofolate reductase in bacteria. It also partially inhibits the human enzyme with extended use.

Oral contraceptives — Some evidence for modest folate reduction with long-term combined OCP use, though the effect is less pronounced than with the medications above.

Special Populations with Higher Folate Depletion Risk

Crohn's Disease and IBD

Crohn's disease reduces folate absorption through multiple mechanisms: small intestinal inflammation reduces absorptive surface area, sulfasalazine competitively inhibits folate absorption, and methotrexate used in moderate-to-severe IBD directly antagonizes folate. Crohn's patients have both a high rate of RAS and a high rate of folate depletion. See Canker Sores and Crohn's Disease.

Celiac Disease

Celiac disease damages the proximal small intestine — where folate absorption primarily occurs — through villous atrophy. Folate malabsorption is a recognized consequence of untreated celiac. Patients on a strict gluten-free diet who achieve full intestinal healing often see both folate status and canker sore frequency normalize. See Gluten-Free Diet and Canker Sores.

Pregnancy

Folate requirements roughly double during pregnancy due to fetal development demands. Pregnant patients on marginal folate intake may develop functional deficiency. Pregnancy-safe canker sore management is a distinct topic — see Canker Sores and Pregnancy.

Alcohol Use

Alcohol directly interferes with folate metabolism at multiple steps: it impairs intestinal absorption, reduces hepatic storage, and increases renal excretion of folate. Chronic alcohol use is one of the most common causes of clinically significant folate deficiency. Even moderate consistent alcohol consumption can lower folate status over time.

Testing Before Supplementing

Rather than supplementing blind, getting your folate status tested is straightforward and informative:

• Serum folate — reflects recent dietary intake (past 1–2 weeks). Can look normal even when tissue stores are depleted if you've eaten well recently.
• RBC folate — a better long-term marker reflecting tissue stores over the prior 3 months. This is the more clinically relevant test for chronic canker sore workup.
• Homocysteine — elevated homocysteine is a functional indicator of folate or B12 deficiency even when serum levels appear normal. Both deficiencies impair the remethylation of homocysteine to methionine. An elevated result points toward folate or B12 (or both) as a problem even if serum levels are borderline.

Reference ranges worth knowing: serum folate below 3 ng/mL is generally considered deficient; 3–5 ng/mL is borderline and clinically relevant in the context of recurrent RAS. RBC folate below 140 ng/mL is deficient by most lab standards. Some clinicians use a higher cutoff of 200–300 ng/mL for RBC folate in RAS patients given the mucosal demand for folate.

If you're already investigating canker sore causes with your doctor, asking to add folate, B12, and homocysteine to the panel costs little and provides useful data. A result at the lower end of normal — technically "in range" — may still be clinically relevant.

What to Take

Preferred form: 5-MTHF (methylfolate), not folic acid — for the MTHFR reasons above.

Dose: 400–800mcg/day of methylfolate for deficiency correction and prevention. This aligns with standard supplemental doses. Higher doses (up to 1mg/day) are used in some clinical protocols for documented deficiency or when MTHFR impairment is significant.

Combination approach: Folate and Vitamin B12 are metabolically linked — both are required for homocysteine remethylation, and deficiency in either elevates homocysteine. A combination methylfolate + methylcobalamin supplement addresses both simultaneously, avoids the masking problem, and covers the two most evidence-linked micronutrients in RAS in one product.

This product provides 1,000mcg methylcobalamin + 400mcg methylfolate — both in bioactive forms that bypass conversion enzyme requirements:

Dietary Sources of Folate

If supplementation feels excessive and deficiency is marginal, optimizing dietary intake is a worthwhile step — with one important caveat: cooking destroys 50–90% of food folate, so raw or minimally cooked preparation matters significantly.

The MTHFR caveat applies here too: if you have significant MTHFR impairment, dietary folate still goes through the same enzymatic conversion pathway. Dietary optimization helps at the margins but won't fully compensate for major MTHFR impairment.

Folate vs. Vitamin B12: Which Matters More for Canker Sores?

For canker sores specifically, Vitamin B12 has stronger evidence — there is an RCT showing benefit even in non-deficient patients, which is the gold standard. Folate's evidence is concentrated in deficiency-correction studies.

However, because both nutrients work together in the same methylation pathway, and because deficiency in one can mask deficiency in the other, testing both and supplementing both in their active forms is the rational approach.

The two are complementary, not competing. See Vitamin B12 and Canker Sores for the full evidence breakdown on B12.